论文部分内容阅读
目的：观察瑞舒伐他汀联合福辛普利治疗糖尿病肾病的临床疗效。方法90例糖尿病肾病患者随机分为福辛普利组和联合用药组各45例。福辛普利组给予福辛普利10mg，口服，1次/ d；联合用药组给予瑞舒伐他汀与福辛普利，瑞舒伐他汀10mg，口服，1次/ d，福辛普利用法同前组。2组疗程均为24周，观察2组治疗前后的尿微白蛋白排泄率（UAER）、24h 尿蛋白、血肌酐（Scr）、血脂、血压等指标。结果治疗后，2组 UAER 与24h 尿蛋白均降低，差异有统计学意义（P ﹤0.01）。联合用药组 UAER、24h 尿蛋白降低幅度大于福辛普利组，差异有统计学意义（ P ﹤0.01），2组 Scr 与空腹血糖均下降，差异无统计学意义（P ﹥0.05）。2组血脂和血压降低均有所改善，差异有统计学意义（P ﹤0.01），联合用药组血脂改变程度优于福辛普利组，差异有统计学意义（P ﹤0.01）。结论瑞舒伐他汀钙联合福辛普利治疗糖尿病肾病，对肾脏保护有协同作用。“,”Objective To observe the clinical efficacy of rosuvastatin combined with fosinopril in the treatment of dia-betic nephropathy. Methods 90 cases of patients were randomly divided into fosinopril group and combination therapy group, each of 45 cases. The fosinopril group were treated with fosinopril 10 mg,po,qd;the combination therapy group were treated with rosuvastatin 10 mg,po,qd and fosinopril 10 mg,po,qd. Both groups were treated for 24 weeks. The urinary albumin excre-tion rate(UAER),24-hour urine protein,serum creatinine(Scr),blood lipid and blood pressure of 2 groups were observed and recorded before and after the treatment. Results After treatment,the UAER and 24 h urine protein decreased in two groups, the differences were statistically significant(P ﹤ 0. 01). But the decreased degree of UAER,24 h urine protein in combination therapy group was greater than those in fosinopril group,the differences were statistically significant(P ﹤ 0. 01). The Scr and fasting blood glucose decreased in two groups with no significant difference among them(P ﹥ 0. 05). The blood lipid and pres-sure were improved in two groups,the differences were statistically significant(P ﹤ 0. 01),especially in combination therapy group(P ﹤ 0. 01). Conclusion Rosuvastatin and fosinopril in combination therapy is superior to monotherapy in the treat-ment of diabetic nephropathy.